Evidence map›Paper›PMID 35108455›Full record

ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2022

Postoperative nonsteroidal anti-inflammatory drugs in relation to recurrence, survival and anastomotic leakage after surgery for colorectal cancer.

Oskar Grahn, Mathias Lundin, Stephen J Chapman, Jörgen Rutegård, Peter Matthiessen, Martin Rutegård

Open access · hybridAbstract read
In one paragraph

Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Considerations for Care of the Cancer Patient.International anesthesiology clinics · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Postoperative nonsteroidal anti-inflammatory drugs in relation to recurrence, survival and anastomotic leakage after surgery for colorectal cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Oskar GrahnDepartment of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden.ORCID 0000-0002-7206-6493
Mathias LundinDepartment of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden.
Stephen J ChapmanLeeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.ORCID 0000-0003-2413-5690
Jörgen RutegårdDepartment of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden.
Peter MatthiessenDepartment of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Martin RutegårdDepartment of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden.
Umeå University · SEÖrebro University · SEUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of this work was to investigate whether nonsteroidal anti-inflammatory drugs (NSAIDs) could be beneficial or harmful when used perioperatively for colorectal cancer patients, as inflammation may affect occult disease and anastomotic healing.

methodThis is a protocol-based retrospective cohort study on colorectal cancer patients operated on between 2007 and 2012 at 21 hospitals in Sweden. NSAID exposure was retrieved from postoperative analgesia protocols, while outcomes and patient data were retrieved from the Swedish Colorectal Cancer Registry. Older or severely comorbid patients, as well as those with disseminated or nonradically operated tumours were excluded. Multivariable regression with adjustment for confounders was performed, estimating hazard ratios (HRs) for long-term outcomes and odds ratios (ORs) for short-term outcomes, including 95% confidence intervals (CIs).

resultsSome 6945 patients remained after exclusion, of whom 3996 were treated at hospitals where a NSAID protocol was in place. No association was seen between NSAIDs and recurrence-free survival (HR 0.97, 95% CI 0.87-1.09). However, a reduction in cancer recurrence was detected (HR 0.83, 95% CI 0.72-0.95), which remained significant when stratifying into locoregional (HR 0.68, 95% CI 0.48-0.97) and distant recurrences (HR 0.85, 95% CI 0.74-0.98). Anastomotic leakage was less frequent (HR 0.69%, 95% CI 0.51-0.94) in the NSAID-exposed, mainly due to a risk reduction in colo-rectal and ileo-rectal anastomoses (HR 0.47, 95% CI 0.33-0.68).

conclusionThere was no association between NSAID exposure and recurrence-free survival, but an association with reduced cancer recurrence and the rate of anastomotic leakage was detected, which may depend on tumour site and anastomotic location.

Indexed as

Anastomotic LeakColorectal NeoplasmsAnti-Inflammatory Agents, Non-SteroidalHumansRetrospective StudiesRisk FactorsAnti-Inflammatory Agents, Non-Steroidalcolon cancerleakNSAIDoncological outcomespostoperative complicationsrectal cancer

Identifiers

PMID35108455
PMCPMC9541253
OpenAlexW4210757548

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.